As Cipla, Novartis Cross Onbrez Swords, Others May Jump In
This article was originally published in PharmAsia News
Executive Summary
After a brief lull, patent-related tussles are back in the Indian pharmaceutical industry. Cipla’s recent submission to the Indian government to review Novartis’ Onbrez patent may potentially prompt smaller drug makers to follow the same path and gain authorization to launch their own variants of patented brands.